Fact-checked by Grok 2 weeks ago

Enterococcus

Enterococcus is a of Gram-positive, facultative anaerobic bacteria in the phylum Firmicutes, characterized by ovoid cocci that typically occur in pairs () or short chains. These resilient microorganisms thrive in diverse environments due to their for high concentrations (up to 6.5%), bile salts, wide pH ranges, and temperatures from 10°C to 45°C, with optimal growth at 35–37°C. They are homofermentative producers, catalase-negative, and non-spore-forming, and were originally classified within the streptococci before being distinguished as a separate in 1984 based on DNA hybridization and 16S rRNA sequencing. The genus comprises approximately 66 recognized species, with Enterococcus faecalis and Enterococcus faecium being the most prevalent and clinically relevant, accounting for about 75–90% of human infections. Ubiquitous in nature, enterococci are commensal inhabitants of the gastrointestinal tracts of humans and animals (comprising less than 1% of the human gut microbiota), as well as soil, water, plants, sewage, and fermented foods like cheese and sausages. As opportunistic pathogens, enterococci are a leading cause of healthcare-associated infections, including urinary tract infections (15–20% of cases), bacteremia, , and infections, particularly in immunocompromised patients. Their pathogenicity is enhanced by virulence factors such as adhesins, cytolysins, gelatinase, and formation, alongside intrinsic and acquired to antibiotics like cephalosporins, aminoglycosides, and (in vancomycin-resistant enterococci, or VRE strains). While some strains show probiotic potential through production and gut health benefits, safety concerns arise from their association with multidrug and nosocomial spread.

Taxonomy and Classification

History

The genus Enterococcus traces its origins to 1899, when French microbiologist Léon Thiercelin and his colleague Pierre Jouhaud first described diplococci isolated from human fecal samples, terming them "entérocoques" due to their intestinal habitat and chain-forming morphology. These organisms were initially classified within the genus Streptococcus as part of the broader group of lactic acid-producing cocci, reflecting the limited taxonomic tools available at the time. In , advancements in serological and physiological classification refined their position. Rebecca Lancefield's work on streptococcal grouping identified these fecal isolates as Lancefield group D streptococci, distinguished by their ability to grow in 6.5% and hydrolyze esculin. J.M. Sherman further delineated group D into enterococcus-like species based on heat resistance and environmental adaptability, highlighting their role in early 20th-century studies where fecal streptococci served as indicators of contamination from . The formal taxonomic separation of Enterococcus from occurred in 1984, proposed by Karl-Heinz Schleifer and Renate Kilpper-Bälz, who used 16S rRNA sequencing, DNA-DNA hybridization, and phenotypic traits—such as motility and growth at elevated temperatures—to establish it as a distinct within the order . This reclassification was solidified by 1980s molecular studies confirming phylogenetic divergence, with E. faecalis and E. faecium as the . Recent genomic sequencing has further expanded the genus, with a 2024 study analyzing over 7,000 strains revealing hidden diversity and describing 18 novel Enterococcus species, enhancing understanding of their evolutionary relationships and ecological niches through whole-genome phylogenomics.

Species and Characteristics

The genus Enterococcus belongs to the phylum Bacillota and the family Enterococcaceae, encompassing more than 70 recognized species that are primarily lactic acid bacteria. Among these, Enterococcus faecalis and Enterococcus faecium are the most clinically significant in humans, accounting for approximately 90-95% and 5-10% of isolates from clinical samples, respectively. Morphologically, enterococci are Gram-positive cocci that typically appear spherical or ovoid, arranged in pairs () or short chains, and they are non-spore-forming. They are facultative , capable of growth in both aerobic and anaerobic conditions. Key biochemical characteristics include being catalase-negative, which distinguishes them from many other Gram-positive cocci, and positive for bile-esculin hydrolysis, enabling identification via the blackening of media containing esculin and bile salts. They demonstrate robust growth in 6.5% NaCl broth and at temperatures ranging from 10°C to 45°C, reflecting their environmental adaptability. Enterococci ferment carbohydrates such as glucose as a primary energy source, producing as the main end product, while fermentation is species-specific—for instance, E. faecalis typically ferments , whereas E. faecium often does not. Less common species include Enterococcus durans, which shares many traits with E. faecium but is more frequently associated with food sources; Enterococcus gallinarum, notable for its motility via peritrichous flagella and intrinsic low-level resistance; and Enterococcus casseliflavus, distinguished by its yellow pigmentation on and motility, often found in plant-associated environments.

Physiology

Metabolic Properties

Enterococci exhibit a primarily fermentative , relying on the Embden-Meyerhof-Parnas pathway for the catabolism of sugars such as glucose, which results in homolactic fermentation producing as the major end product and yielding a net of 2 ATP molecules per glucose molecule through . This process involves NAD+-dependent L- dehydrogenases (encoded by ldh-1 and ldh-2 genes), which regenerate NAD+ under conditions, enabling sustained energy production in oxygen-limited environments typical of the . Nutritionally, Enterococcus species grow readily on simple media containing glucose as the primary carbon source, but they can utilize a diverse array of substrates to supplement energy needs, including citrate, which is fermented to , , , , and via citrate-specific operons. Additionally, they employ the arginine dihydrolase pathway to catabolize , converting it to , , and , which not only generates 1 ATP per arginine molecule but also alkalinizes the environment by producing ammonia. This pathway requires a minimal fermentable (at least 0.05%) for biosynthetic purposes during arginine utilization. Enterococci possess various enzyme systems that support their metabolic versatility, including esterases and lipases, though their presence and activity are strain-dependent, with generally showing higher lipolytic activity compared to other species. Species-specific differences are evident in utilization. These demonstrate notable adaptations for , tolerating growth across a broad range from 4.6 to 9.9, facilitated by an acid tolerance response that includes proton pumps such as the F0F1-ATP synthase and Na+/H+ antiporters to maintain cytosolic under acidic stress.

Growth and Survival

Enterococci thrive under optimal temperatures of 35–37°C, where they exhibit rapid replication with doubling times ranging from 30 to in nutrient-rich media such as broth. As facultative anaerobes, they adapt to varying oxygen levels; under microaerophilic conditions, employs a bd-type respiratory to support efficient and production. This enables the bacteria to utilize oxygen as a terminal when available, enhancing growth rates compared to strictly fermentative metabolism. These bacteria demonstrate robust survival against osmotic stress, tolerating NaCl concentrations up to 6.5%, a trait that distinguishes the and aids persistence in saline environments. uptake systems facilitate this resilience; for instance, actively accumulates glycine betaine from the medium during salt exposure, which stabilizes cellular proteins and maintains without inhibiting growth. Additionally, Enterococci exhibit heat resistance, surviving temperatures up to 60°C for short periods, particularly when embedded in biofilms or desiccated matrices that protect against and drying stresses. Adaptability to extremes further bolsters their survival, with growth possible across a range of 4–10, allowing colonization of acidic or alkaline niches. In response to oxygen availability, metabolic shifts occur; under aerobic conditions, diverts pyruvate toward and production alongside , optimizing ATP yield through mixed-acid . Persistence is also enhanced by formation, regulated by the quorum-sensing in E. faecalis, which coordinates gelatinase production and matrix development to communities on abiotic surfaces like catheters or mucosal linings. This structured confers to environmental insults, prolonging viability in hostile settings.

Ecology and Habitat

Natural Reservoirs

Enterococci are prominent commensal in the human , particularly in the lower intestine, where they constitute approximately 1% of the fecal . Typical concentrations range from 10^4 to 10^6 colony-forming units (CFU) per gram of wet feces, with being more prevalent than in healthy adults. In animal hosts, enterococci commonly colonize the intestines of various mammals, such as pigs and , as well as like chickens, where including E. faecalis, E. faecium, and E. hirae predominate. They are also found in the guts of , including houseflies and wild , contributing to zoonotic risks through the in and production. Colonization by enterococci typically begins at birth, acquired through exposure to maternal vaginal and gastrointestinal flora during or via oral routes from and environmental sources in formula-fed infants. Stable gut colonization persists throughout life, modulated by dietary factors and disruptions like use, which can alter microbial competition and promote persistence of resilient enterococcal strains. Beyond biological hosts, enterococci inhabit non-human reservoirs such as , , and water bodies, primarily introduced through fecal contamination from humans and animals. In these environments, they demonstrate persistence, with detections in temperate and tropical , on plant surfaces like , and in systems including coastal waters and sediments, often serving as indicators of .

Environmental Distribution

Enterococci are ubiquitous in non-host environments, primarily entering these habitats through fecal contamination from animal and human reservoirs. In systems, they serve as key fecal indicator bacteria, signaling the presence of in freshwater, , and estuarine waters worldwide. Their global distribution is facilitated by effluents, which transport them into rivers, coastal areas, and sediments, where densities can exceed those in overlying water columns. These bacteria exhibit notable resilience in water treatment processes, surviving chlorination more effectively than coliforms due to their intrinsic salt tolerance, which allows growth in up to 6.5% NaCl and persistence in saline conditions like . This adaptability enables enterococci to endure disinfection doses that inactivate other indicators, such as reductions of over five orders of magnitude only at higher levels (11.8–23.2 mg/L over 15 minutes). Seasonal variations influence their abundance in surface waters, with species like more prevalent in freshwater during summer months, reflecting temperature-driven proliferation and runoff patterns. Transmission occurs via contaminated food chains, notably from , and potentially through in settings like hospitals where fecal matter is handled. In terrestrial environments, enterococci ingress soil primarily via manure application in agriculture, persisting in tropical, temperate, and subtropical soils at densities often surpassing 1,000 MPN/g. They colonize rhizospheres, where their presence correlates inversely with time post-contamination, integrating into plant-associated microbial communities. As components of soil microbiota, enterococci contribute to nutrient cycling by participating in the decomposition of organic matter, aiding the breakdown of fecal inputs and enhancing soil fertility processes. Longer persistence occurs in cooler seasons like spring and winter, contributing to episodic contamination of stormwater and agricultural runoff. Evolutionarily, enterococci trace their origins to approximately 425–500 million years ago during the Era, emerging as gut symbionts in early terrestrial animals transitioning from marine ancestors. Traits such as desiccation resistance and metabolic versatility, honed in host intestines, facilitated their expansion into diverse abiotic environments following vertebrate evolution, enabling widespread ecological adaptation beyond primary animal reservoirs.

Role in Health and Disease

Commensal Flora

Enterococci, particularly and , serve as commensal members of the human gastrointestinal microbiome, contributing to microbial and host physiology. These bacteria colonize the intestinal tract early in life and persist at low levels in healthy adults, where they participate in metabolic processes that support nutrient availability and microbial balance. By aiding in the production of essential compounds and competing for resources, enterococci help maintain a stable gut , preventing overgrowth of harmful pathogens. In the microbiome, enterococci contribute to vitamin K synthesis in the form of menaquinones, such as MK-7, which are produced via bacterial pathways and absorbed by the host to meet a significant portion of dietary requirements. They also facilitate short-chain (SCFA) fermentation indirectly by modulating the composition, enhancing the activity of SCFA-producing taxa and supporting anti-inflammatory effects through metabolites like butyrate. Additionally, enterococci exhibit competitive exclusion against pathogens such as ; certain strains, including those isolated from infant feces, inhibit toxin production and growth of toxigenic C. difficile via secretion and competition, thereby reducing colonization risk during dysbiotic states. Enterococci interact with the host through adherence mechanisms involving pili and surface proteins, such as the endocarditis- and biofilm-associated pilus (Ebp) and adhesin Ace, which bind to intestinal mucins and extracellular matrix components, promoting stable colonization without disrupting epithelial integrity. These interactions also modulate immune responses; for instance, E. faecalis reduces pro-inflammatory cytokine and chemokine production, such as IL-8 and TNF-α, during steady-state colonization, fostering tolerance and limiting excessive inflammation in the gut mucosa. Population dynamics of enterococci vary by age and environmental factors; in infants, particularly premature ones, they constitute a higher proportion of the gut flora due to early and lower microbial diversity, but this proportion declines to approximately 1% in healthy adults as the matures. disruptions, such as broad-spectrum treatments, induce by depleting competing commensals, leading to enterococcal overgrowth and increased relative abundance, which can persist for months and heighten risks. Species-specific roles highlight E. faecalis as a key contributor to gut barrier integrity; through regulated degradation via metalloproteases like GelE, it facilitates mucin turnover, releasing nutrients for the while maintaining epithelial tight junctions and preventing invasion. This process supports overall in the commensal context, contrasting with dysregulated activity in pathogenic states.

Pathogenic Mechanisms

Enterococci are opportunistic pathogens that employ a range of virulence factors to facilitate tissue invasion and damage during infection. Cytolysin, also known as hemolysin, is a two-component toxin produced primarily by Enterococcus faecalis that lyses both eukaryotic host cells and competing Gram-positive bacteria, contributing to cell death and enhanced lethality in models of endocarditis and endophthalmitis. Gelatinase, a zinc metalloprotease encoded by the gelE gene, degrades host extracellular matrix components such as collagen and laminin, promoting tissue invasion and biofilm maturation. Similarly, serine protease, encoded by sprE, aids in host protein degradation and immune modulation, further supporting systemic spread and pathogenesis in animal models. Aggregation substance, a surface protein encoded by asa1, enhances bacterial adhesion to host platelets and epithelial cells, facilitating biofilm formation and platelet binding that exacerbates endovascular infections. To evade host defenses, enterococci utilize structures and proteins that resist phagocytosis and complement-mediated killing. The bacterial capsule, present in approximately 40% of clinical E. faecalis isolates and encoded by the cpsC-K operon, masks opsonic complement component C3, delaying phagocytic uptake by macrophages and neutrophils. The enterococcal surface protein (Esp), a cell wall-anchored adhesin, promotes biofilm formation and inhibits phagocytosis by altering host inflammatory responses, while also enhancing intracellular survival within neutrophils. The enterococcal polysaccharide antigen (EPA), a conserved rhamnose-based surface polysaccharide, protects against serum killing and reduces bacterial aggregation to limit macrophage recognition; mutants lacking EPA decorations exhibit increased phagocytosis susceptibility in vitro. Opportunistic pathogenesis in enterococci is often triggered by disruptions in host . formation on indwelling medical devices, such as urinary catheters and intravascular lines, is mediated by pili (e.g., Ebp) and adhesins, enabling persistent colonization and over 20,000 catheter-associated urinary tract reported to the CDC from 2011 to 2014. therapy disrupts the normal , allowing enterococcal overgrowth—often leading to near-monocultures in the intestine—and subsequent translocation to sterile sites like the bloodstream. , as seen in elderly patients, recipients, or transplant hosts, further promotes invasion by impairing phagocytic clearance and innate immunity, increasing infection severity. The genetic underpinnings of these mechanisms involve mobile elements and regulatory systems that enhance adaptability. genes for factors like cytolysin and aggregation substance are frequently carried on plasmids, such as pheromone-responsive conjugative plasmids (e.g., pCF10), which facilitate horizontal transfer and dissemination among enterococcal populations. , mediated by systems like the regulon in E. faecalis, coordinates expression of determinants including gelatinase and in response to , optimizing development and host invasion. These elements underscore the evolutionary success of enterococci as pathogens in disrupted microbial ecosystems.

Clinical Infections

Urinary Tract and Wound Infections

Enterococci, particularly , are a leading cause of urinary tract infections (UTIs), accounting for 15-20% of nosocomial UTIs . These infections are frequently associated with indwelling urinary , where enterococci rank as the second most common pathogen in catheter-associated UTIs (CAUTIs), contributing to over 30% of such cases in hospital settings. E. faecalis predominates in these infections, often forming biofilms on catheter surfaces that enhance persistence and complicate eradication. Symptoms typically include , urinary frequency, urgency, and suprapubic pain, accompanied by on , though elderly or catheterized patients may present with atypical or minimal signs. Wound infections involving enterococci commonly occur at surgical sites or in diabetic foot ulcers, where they contribute to polymicrobial infections and tissue damage. In diabetic foot infections, enterococci are isolated in up to 35% of cases, particularly in patients with peripheral and , and itself serves as a key by impairing and . These infections often manifest as , , or formation with accumulation, exacerbating local and delaying closure. Surgical site involvement is similarly linked to contamination during procedures, leading to delayed healing in vulnerable hosts. Epidemiologically, enterococcal UTIs occur frequently in community settings among elderly women, where significant affects approximately 20% of community-dwelling women over 65 years. In contrast, nosocomial cases predominate in hospitalized patients, often arising from outbreaks transmitted via contaminated instruments or hands, with an typically ranging from 4 to 10 days post-exposure. infections follow similar patterns, with higher incidence in diabetic populations and healthcare facilities where cross-contamination occurs. Complications from enterococcal UTIs include ascending infection to the upper urinary tract, resulting in or perinephric abscesses, particularly in the presence of urinary obstruction or catheterization. These localized infections carry a risk of bacteremia, estimated at 5-10% in complicated cases, serving as a portal for further dissemination if untreated. mechanisms, such as those mediated by enterococcal surface proteins, facilitate this ascent but are secondary to local factors in these manifestations.

Systemic Infections

Systemic infections caused by Enterococcus species represent severe manifestations of enterococcal disease, often resulting from dissemination from primary foci such as the gastrointestinal or genitourinary tracts. Bacteremia, a common systemic presentation, typically arises from breaches in these mucosal barriers, leading to hematogenous spread. Patients commonly exhibit fever and signs of , including and organ dysfunction, reflecting the bacterium's ability to evade host defenses and proliferate in the bloodstream. Mortality rates for enterococcal bacteremia range from 20% to 35% at 30 days, with E. faecium infections associated with higher lethality (up to 34.6%) compared to E. faecalis (21.4%), attributed to greater factors in E. faecium. Endocarditis due to Enterococcus accounts for 5% to 10% of all cases of infective endocarditis and 8% to 32% of enterococcal bacteremia episodes, positioning it as the third most common community-acquired cause in North America. The infection involves the formation of vegetations—complex biofilms of bacteria, fibrin, and platelets—on heart valves, particularly affecting the elderly or those with underlying valve abnormalities. Diagnosis relies on the modified Duke criteria, which integrate major elements like positive blood cultures and echocardiographic evidence of endocardial involvement with minor criteria such as predisposing conditions. Intravenous drug use elevates risk, as non-sterile injections provide a portal for bacterial entry, though enterococci are less frequent culprits than staphylococci in this population. Meningitis caused by Enterococcus is rare, primarily occurring in neonates or following neurosurgical procedures such as shunt placements. It manifests with (CSF) pleocytosis, typically showing elevated counts (median around 173 cells/mL), alongside Gram-positive cocci in chains on culture. Treatment demands high-dose antibiotics that achieve adequate CSF penetration despite the blood-brain barrier, often requiring combinations like with an based on susceptibility testing. Other systemic infections include in patients undergoing , where Enterococcus accounts for approximately 3% of peritonitis episodes and is linked to poorer outcomes, including a 27.8% mortality rate in affected cases. Overall, enterococci contribute to 10% to 15% of nosocomial , underscoring their prominence in healthcare-associated settings.

Antibiotic Resistance

Intrinsic and Acquired Resistance

Enterococci exhibit intrinsic resistance to several classes of antibiotics due to inherent physiological and structural features that limit drug efficacy. A primary mechanism is the expression of low-affinity penicillin-binding proteins (PBPs), such as PBP4 in Enterococcus faecalis and PBP5 in Enterococcus faecium, which bind weakly to β-lactam antibiotics like penicillins and cephalosporins, resulting in minimum inhibitory concentrations (MICs) typically ranging from 2–16 µg/ml. This low affinity contributes to moderate resistance against β-lactams, though most strains remain susceptible to ampicillin at clinically achievable levels. Additionally, enterococci display intrinsic low-level resistance to aminoglycosides, such as gentamicin and streptomycin, primarily due to impermeability of the cell wall, which restricts drug entry and limits uptake to levels insufficient for ribosomal inhibition (MICs up to 500 µg/ml for streptomycin in E. faecalis). Efflux pumps, including the ABC-type transporter encoded by the lsa gene in E. faecalis, further confer intrinsic resistance to lincosamides like clindamycin by actively expelling the antibiotic from the cell. Acquired resistance in enterococci arises through and mutational events, enhancing their adaptability in antibiotic-exposed environments. Plasmid-mediated β-lactamases, encoded by genes, hydrolyze β-lactam antibiotics and have been documented since in E. faecalis, occasionally leading to high-level penicillin resistance when combined with PBP alterations. For , acquired resistance often involves ribosomal target modifications, including in 23S rRNA or ribosomal proteins L4 and L22, which reduce drug binding; these can occur spontaneously or via acquisition of erm genes that methylate the , though provide an alternative pathway in some strains. Conjugation plays a central role in disseminating these resistance determinants, facilitated by sex pheromone-responsive plasmids in E. faecalis (e.g., pCF10), where chromosomally encoded pheromones like cCF10 induce plasmid at high efficiency (up to 10⁻³ per donor cell), promoting the spread of resistance genes across bacterial populations. Epidemiologically, enterococci maintain relatively high susceptibility to , with 80–90% of clinical isolates—predominantly E. faecalis—remaining sensitive, reflecting the limitations of intrinsic mechanisms against this agent. In contrast, high-level gentamicin resistance (HLGR, ≥500 µg/ml) is increasingly prevalent, affecting 20–55% of isolates in hospital settings worldwide, driven by the bifunctional enzyme encoded by the aac(6')-Ie-aph(2")-Ia , which acetylates and phosphorylates the to prevent ribosomal penetration. This is highly conserved, detected in over 90% of HLGR strains, and often linked to transposons like Tn5281, underscoring its role in the rising burden of multidrug-resistant enterococcal infections. Detection of these resistance mechanisms relies on standardized testing to guide clinical decisions. or agar dilution methods determine MICs for β-lactams and low-level s per Clinical and Laboratory Standards Institute (CLSI) guidelines, while high-level resistance, including HLGR, is specifically assessed using brain-heart infusion agar supplemented with 500 µg/ml gentamicin. Gradient diffusion strips, such as , provide a convenient alternative for precise MIC gradients, particularly useful for confirming ribosomal or efflux-mediated resistance in and .

Vancomycin-Resistant Enterococci

Vancomycin-resistant enterococci (VRE) were first reported in 1986 in a British hospital, marking the initial emergence of glycopeptide in this genus nearly three decades after 's introduction into . The primary of involves the acquisition of van operons, particularly vanA and vanB, which are typically carried on such as the transposon Tn1546. These operons reprogram synthesis by replacing the terminal D-alanine-D-alanine (D-Ala-D-Ala) in precursors with D-alanine-D-lactate (D-Ala-D-Lac), which has a 1,000-fold lower affinity for , thereby preventing the drug from inhibiting transpeptidation and assembly. This alteration is inducible in the presence of , allowing enterococci to adapt rapidly to selective pressure from glycopeptide exposure. The vanA phenotype confers high-level resistance to both vancomycin (minimum inhibitory concentration [MIC] >256 μg/mL) and teicoplanin, and is inducible, while the vanB phenotype results in lower-level, variable resistance to vancomycin (MIC 4-1,024 μg/mL) but retains susceptibility to teicoplanin. Transmission of these resistance determinants occurs primarily through the Tn1546-like transposons, which facilitate horizontal gene transfer between enterococcal strains and even across genera via conjugation. VanA remains the dominant type globally, though vanB clusters have been increasingly detected in certain regions, contributing to the genetic diversity of VRE. As of 2025, the CDC estimates that approximately 30% of infections caused by Enterococcus spp. are VRE, predominantly E. faecium, with in settings ranging from 20-40% in high-risk settings, reflecting a sustained upward trend driven by nosocomial spread. Key risk factors include prior exposure to or broad-spectrum antibiotics, which disrupt the and select for resistant strains, as well as from or prolonged hospitalization in intensive care units (ICUs). VRE strains are associated with outbreaks in ICUs, where patient colonization precedes invasive infections, leading to increased morbidity and healthcare costs. Recent genomic surveillance efforts, including whole-genome sequencing of clinical and screening isolates, have enhanced outbreak detection and transmission tracking, enabling targeted interventions that reduce healthcare-associated spread in hospital settings.

Treatment and Control

Antimicrobial Therapy

For susceptible Enterococcus strains, or penicillin G serves as first-line therapy, typically administered as 2 g intravenously every 4-6 hours or penicillin G 18-30 million units daily in divided doses, achieving bactericidal activity through inhibition. is recommended as an alternative for patients with allergy, dosed at 15-20 mg/kg intravenously every 8-12 hours with trough levels targeted at 10-20 µg/mL to ensure efficacy against glycopeptide-susceptible isolates. In serious infections such as , with (12 g/day in divided doses) plus gentamicin (3 mg/kg/day in divided doses) is standard for 4-6 weeks, providing synergistic killing by combining inhibition with ribosomal protein synthesis blockade to overcome the organism's tolerance to single agents. For (VRE) infections, at 600 mg intravenously every 12 hours or at 8-12 mg/kg intravenously daily are preferred options, with daptomycin's dose adjusted based on body weight, , and renal function to optimize bactericidal activity. , an oxazolidinone similar to , is emerging as a potential alternative in 2025 clinical evaluations for VRE, showing promise in limited transplant-related cases but lacking broad approval for this indication. In urinary tract infections (UTIs) caused by Enterococcus, oral (100 mg every 6 hours for 5-7 days) or a single 3 g dose of fosfomycin is effective for uncomplicated cases, concentrating in urine to target susceptible strains while minimizing systemic exposure. For complicated UTIs, which are common in healthcare-associated Enterococcus infections, should align with local resistance patterns and the 2025 IDSA guidelines, potentially including broader-spectrum agents if Enterococcus is suspected. Treatment choices are influenced by local resistance patterns, such as high vancomycin resistance rates exceeding 20% in some hospital settings.

Infection Prevention Strategies

Infection prevention strategies for Enterococcus, particularly vancomycin-resistant strains (VRE), emphasize multifaceted hospital protocols to curb transmission in healthcare settings, where outbreaks are most common due to patient colonization and environmental persistence. Hand remains a cornerstone, with and washing preferred over alcohol-based sanitizers in scenarios involving potential co-infections with , as alcohol rubs are ineffective against C. difficile spores that may coexist in high-risk environments. This approach mechanically removes transient Enterococcus from hands, reducing cross-contamination risks during patient care. Isolation protocols are critical for VRE , including precautions such as donning gloves and gowns upon entering of colonized or infected patients to prevent direct and indirect spread. Cohorting of VRE-positive patients in designated areas minimizes to uninfected individuals, while terminal cleaning with bleach-based disinfectants at 1,000 ppm free effectively eliminates environmental reservoirs. These measures, when combined, have demonstrated substantial reductions in VRE incidence in outbreak settings. Device management focuses on minimizing indwelling duration, as prolonged use heightens Enterococcus risk; bundles incorporating aseptic insertion, daily review, and prompt removal—ideally within 48 hours post-procedure when feasible—significantly lower catheter-associated infections. Complementing this, antibiotic stewardship programs restrict unnecessary use to curb selective pressure favoring VRE emergence, promoting narrower-spectrum alternatives where appropriate. Surveillance in high-risk units, such as intensive care and oncology wards, involves active screening of at-risk patients via rectal swabs to detect asymptomatic colonization early. A 2025 study published by the CDC underscores the integration of genomic typing, including whole-genome sequencing, for outbreak investigation, enabling precise strain tracking and targeted interventions to contain Enterococcus transmission. In community settings, basic hygiene education and avoiding unnecessary antibiotic use further support broader prevention efforts.

Industrial and Environmental Applications

Use in Food Fermentation

Enterococci, particularly and , play a significant role as starter or adjunct cultures in the of and products, where they contribute to sensory qualities through specific metabolic pathways. In cheese production, such as Cheddar and varieties, these bacteria metabolize citrate present in milk, producing key flavor compounds like , , and volatile that enhance the characteristic tangy and buttery notes. In fermented sausages, strains are commonly employed as starters during the ripening phase, promoting the breakdown of proteins and to develop complex aromas and ensure product stability. Beyond traditional fermentation, select Enterococcus strains exhibit probiotic potential and are incorporated into gut health supplements. For instance, E. faecium SF68 has been studied for its ability to modulate , with clinical evidence demonstrating its effectiveness in preventing and treating acute , including antibiotic-associated cases. Meta-analyses of randomized controlled trials support the broader use of like SF68, showing a significant reduction in the incidence of antibiotic-associated by up to 60% in various populations. Safety considerations are paramount in the industrial application of Enterococci, as the genus lacks overall (GRAS) status from the U.S. , necessitating strain-specific assessments. Industrial strains are rigorously selected for traits such as non-hemolytic activity on blood agar, absence of genes, and minimal intrinsic or acquired to mitigate risks. Additionally, these strains produce exopolysaccharides that improve the and of fermented foods, while potential pathogenic variants are controlled through and processes like , which effectively inactivate viable cells in heat-treated products.

Indicator in Water Quality

Enterococcus species, particularly and , are widely used as microbial indicators of fecal contamination in recreational and , providing a more specific assessment of pollution from human and animal sources compared to total coliforms, which can originate from non-fecal environmental reservoirs. These bacteria are especially valuable in marine and estuarine environments, where they demonstrate greater persistence and survival than , allowing for reliable detection of or runoff impacts over extended periods. The U.S. Environmental Protection Agency (EPA) has established recreational water quality criteria recommending enterococci levels below 35 colony-forming units (CFU) per 100 mL in beach waters to protect from gastrointestinal illnesses associated with fecal pathogens. Standard testing for enterococci employs membrane filtration techniques, where water samples are passed through a 0.45 μm filter to capture , which are then cultured on selective such as m-Enterococcus agar. The filter is incubated at 41°C for to selectively promote the of fecal enterococci, enabling direct of red or maroon colonies indicative of these organisms. This approach is standardized in ISO 7899-2, which outlines the membrane filtration method for enumerating intestinal enterococci in water, ensuring consistent and comparable results across laboratories. Regulatory frameworks incorporate enterococci monitoring to safeguard waters. Under the Union's Directive 2006/7/EC, coastal and transitional bathing sites must maintain intestinal enterococci below 100 CFU/100 mL (95th percentile) for "excellent" classification and below 200 CFU/100 mL for "good" status, with sufficient quality requiring no exceedance of 185 CFU/100 mL (90th percentile). Ongoing research and developments as of 2025, driven by climate-induced increases in runoff and pollution events, are integrating quantitative (qPCR) methods for same-day enterococci detection, with validation efforts by the EPA and calls for modernization of the Directive. Despite their utility, enterococci face limitations as indicators: not all detected strains are pathogenic to , potentially leading to conservative risk assessments, and elevated levels in waters dominated by animal fecal pollution may overestimate health threats since animal-derived enterococci correlate less strongly with human-specific pathogens.

References

  1. [1]
    The Enterococcus: a Model of Adaptability to Its Environment
    Jan 30, 2019 · The enterococci are resilient and versatile species able to survive under harsh conditions, making them well adapted to the health care environment.
  2. [2]
    Enterococcus Infections - StatPearls - NCBI Bookshelf - NIH
    Enterococci are Gram-positive facultative anaerobic cocci in short and medium chains, which cause difficult-to-treat infections in the nosocomial setting.
  3. [3]
    The Genus Enterococcus: Between Probiotic Potential ... - Frontiers
    Enterococci are lactic acid bacteria (LAB) comprising both pathogenic and commensal microorganisms ubiquitous in environment even as gut symbionts. Due to their ...
  4. [4]
    The Enterococcus: a Model of Adaptability to Its Environment - PMC
    The term “entérocoque” was first coined by Thiercelin in 1899, when he described gut commensal bacteria with the ability to become pathogenic (16).
  5. [5]
    Enterococcus Diversity, Origins in Nature, and Gut Colonization - NCBI
    Feb 2, 2014 · Phylogenetically, the genus Enterococcus belongs to the low GC branch of Gram-positive bacteria (i.e. 37.5% of GC in the Enterococcus faecalis ...Abstract · Introduction · The Enterococcus genus... · Enterococcal species: Natural...
  6. [6]
    THE GROUP D STREPTOCOCCI - PMC - NIH
    1937 Mar;33(3):275–282. doi: 10.1128/jb.33.3.275-282.1937. [DOI] [PMC free article] [PubMed] [Google Scholar]; Sherman J. M. THE STREPTOCOCCI. Bacteriol Rev ...
  7. [7]
    Detection and Sanitary Significance of Fecal Streptococci in Water
    Evidence suggests that the fecal streptococci are more practical and reliable indicators of fecal contamination of water than the coliforms. The author.Missing: early | Show results with:early
  8. [8]
    Phenotypic identification of the genus Enterococcus and ...
    The genus name Enterococcus (Thiercelin and Jouhaud. 1903) was revived by Schleifer and Kilpper-Balz (1984) for bacteria previously named Streptococcus faecalis ...
  9. [9]
    Global diversity of enterococci and description of 18 previously ...
    Over 60 enterococcal species are now known. Two species, Enterococcus faecalis and Enterococcus faecium, are common constituents of the human microbiome. They ...
  10. [10]
    The Physiology and Metabolism of Enterococci - NCBI
    Feb 15, 2014 · Lactate is the major end product of enterococcal fermentation during growth on excess glucose under reducing conditions. It is generated by the ...
  11. [11]
    Gene Structure, Organization, Expression, and Potential Regulatory ...
    Enteroccus faecalis is the paradigm for biochemical studies on the arginine deiminase (ADI) pathway of fermentative arginine catabolism.
  12. [12]
    Enterococcus - an overview | ScienceDirect Topics
    Enterococci may have lipases and/or esterases, but the presence of such enzymes is strain dependent. Generally, Ec. faecalis exhibits higher lipolytic activity ...
  13. [13]
    Enterococcus - an overview | ScienceDirect Topics
    Enterococcus species grow in a temperature range between 5 °C and 50 °C (with an optimum at 35–37 °C), in 6.5% NaCl, and at a pH of 9.6, surviving heating at 60 ...Missing: esculin | Show results with:esculin
  14. [14]
    Enterococcus faecalis V583 Contains a Cytochrome bd-Type ...
    In this study, we demonstrate thatE. faecalis contains a cytochrome bd-type oxidase which is expressed under some growth conditions.Missing: anaerobiosis | Show results with:anaerobiosis
  15. [15]
    Pathogenicity of Enterococci - PMC - NIH
    Among these traits are the ability to grow over wide temperature and pH ranges, survive desiccation, and grow in the presence of 6.5% NaCl and 40% bile salts ( ...Missing: doubling | Show results with:doubling
  16. [16]
    The osmoprotectant glycine betaine inhibits salt-induced cross ...
    In this report, it has been demonstrated that this bacterium actively accumulates the osmoprotectant glycine betaine (GB) from salt-enriched complex medium BHI.
  17. [17]
    (PDF) Heat resistance of enterococci - ResearchGate
    Aug 10, 2025 · Enterococcus strains can withstand high heating temperatures, they are recognised as the most thermo-resistant among the nonsporulating bacteria.
  18. [18]
    Enterococcus spp. ability to form a dry surface biofilm
    Oct 31, 2025 · All Enterococcus strains formed DSB on stainless steel and other clinical materials. DSB maintained high culturability (5-6 log10) for up to 84 ...Missing: desiccation | Show results with:desiccation
  19. [19]
    The acid tolerance response and pH adaptation of... - F1000Research
    Background: The objective of the present study was to evaluate the acid tolerance response and pH adaptation when Enterococcus faecalis interacted with ...Missing: pumps | Show results with:pumps
  20. [20]
    Global Metabolic Response of Enterococcus faecalis to Oxygen - PMC
    The aim of this study was to determine the impact of oxygen on the metabolism of the facultative anaerobe Enterococcus faecalis.Missing: anaerobiosis | Show results with:anaerobiosis<|separator|>
  21. [21]
    Role of the fsr Quorum-Sensing System in Enterococcus faecalis ...
    Nov 14, 2022 · We found that fsr played an important role in both biofilm formation and serum resistance ability in E. faecalis.
  22. [22]
    Esp-Independent Biofilm Formation by Enterococcus faecalis
    Enterococcus faecalis is a gram-positive opportunistic pathogen known to form biofilms in vitro. In addition, this organism is often isolated from biofilms ...Missing: desiccation | Show results with:desiccation
  23. [23]
    Enterococci and Their Interactions with the Intestinal Microbiome - NIH
    Nov 17, 2017 · Enterococcal strains represent roughly 1% of human fecal microbiota, with E. faecalis and E. faecium being the most common inhabitants (15–19).
  24. [24]
    Enterococci as Indicators of Environmental Fecal Contamination
    Feb 5, 2014 · Enterococci are found in high concentrations in human feces, usually between 104 and 106 bacteria per gram wet weight (Layton, Walters, Lam, ...Introduction · Detection of Enterococci
  25. [25]
    Antimicrobial Resistance in Enterococcus spp. of animal origin - PMC
    Enterococci are natural inhabitants of the intestinal tract in humans and many animals, including food-producing and companion animals.
  26. [26]
    Enterococci in the Environment - PMC - PubMed Central
    The ability of enterococci to grow in the presence of salt (6.5% NaCl) is one of the distinguishing characteristics of the genus (see Enterococci and the Genus ...Missing: doubling | Show results with:doubling
  27. [27]
    Enterococcal colonization of infants in a neonatal intensive care unit
    Colonizing microorganisms originate from the vaginal and gastrointestinal flora of the mother, oral ingestion of breast milk and formula milk, or from ...
  28. [28]
    Maternal vaginal fluids play a major role in the colonization of ... - NIH
    Oral administration of maternal vaginal microbes at birth to restore gut microbiome development in infants born by caesarean section: A pilot randomised ...
  29. [29]
    Indicators: Enterococci | US EPA
    Jan 13, 2025 · Sources of fecal indicator bacteria such as enterococci include wastewater treatment plant effluent, leaking septic systems, stormwater runoff, ...
  30. [30]
    Surveillance of Enterococcus spp. reveals distinct species ... - Nature
    Mar 3, 2020 · Enterococcus species recovered from catch basin wastewater included E. casseliflavus (17%), E. faecium (9%), E. durans (7%), E. faecalis (5%), E ...<|control11|><|separator|>
  31. [31]
    Chlorination of Indicator Bacteria and Viruses in Primary Sewage ...
    Enterococci were more resistant to disinfection than E. coli, particularly at the lower doses of chlorine, but were still completely inactivated within 15 min ...Missing: salt | Show results with:salt
  32. [32]
    Effects of season and water type on the distribution and ...
    Species distribution was influenced by water type and season. Enterococcus faecalis was more likely found in freshwater rivers and in summer, and Ent. faecium ...Missing: evolutionary | Show results with:evolutionary
  33. [33]
    Enterococcus species: insights into antimicrobial resistance and ...
    Dec 4, 2023 · Enterococcus spp. recovered from livestock and raw meat samples were characterized using antimicrobial susceptibility testing and whole-genome sequencing.Missing: aerosolization | Show results with:aerosolization
  34. [34]
    Increase in Multidrug-Resistant Enterococcus spp. in Agricultural ...
    Apr 21, 2021 · The use of animal manure for soil fertilization has been shown to enhance resident soil bacteria's proliferation in agricultural soil [21].Missing: rhizosphere | Show results with:rhizosphere
  35. [35]
    Factors influencing the persistence of enteropathogenic bacteria in ...
    Dec 4, 2020 · Enterococcus detection in the rhizosphere was negatively correlated with time while all three micro-organisms showed positive correlations ...
  36. [36]
    Tracing the Enterococci from Paleozoic Origins to the Hospital - PMC
    We examined the evolutionary history of leading multidrug resistant hospital pathogens, the enterococci, to their origin hundreds of millions of years ago.Missing: symbionts | Show results with:symbionts
  37. [37]
    The Relationship Among Intestinal Bacteria, Vitamin K and ...
    Apr 18, 2022 · Vitamin K is absorbed by the gut, and the intestinal bacteria are a major source of vitamin K in human body. ... The gut microbes, Enterococcus ...
  38. [38]
    Enterococcus faecium GEFA01 alleviates hypercholesterolemia by ...
    Enterococcus faecium GEFA01 alleviates hypercholesterolemia by promoting reverse cholesterol transportation via modulating the gut microbiota-SCFA axis.
  39. [39]
    Enterococcus faecalis Isolated From Infant Feces Inhibits Toxigenic ...
    Sep 24, 2020 · This study aims to identify potential probiotic enterococci strains that act against Clostridioides (Clostridium) difficile strains and ...
  40. [40]
    Sortase-Dependent Proteins Promote Gastrointestinal Colonization ...
    Our data suggest that Ace and the E. faecalis pilus contribute to both mucin adherence and intestinal colonization. However, further work demonstrating direct ...
  41. [41]
    Enterococcus faecalis Modulates Immune Activation and Slows ...
    Reduced cytokine and chemokine levels during steady-state infection suggest that E faecalis can modulate the host immune response in wounds to promote ...
  42. [42]
    The First Microbial Colonizers of the Human Gut: Composition ...
    Nov 8, 2017 · Gram-positive bacteria, such as Staphylococcus, Enterococcus, and clostridia, dominate the gut microbiota of very premature infants during the ...
  43. [43]
    Enterococci and Their Interactions with the Intestinal Microbiome
    Because enterococci exist as commensals, modifying the intestinal microbiome to eliminate enterococcal clinical pathogens poses a challenge.
  44. [44]
    Enterococcus faecalis Metalloprotease Compromises Epithelial ...
    Interestingly, GelE triggered degradation of the extracellular domain of adherence junction protein E-cadherin and the loss of epithelial barrier integrity in ...
  45. [45]
    Pathogenicity of Enterococci | Microbiology Spectrum - ASM Journals
    However, the enterococcal surface protein Esp and the collagen-binding protein Acm have been shown to be important for the pathogenesis of E. faecium IE in a ...
  46. [46]
    Exploring the role of E. faecalis enterococcal polysaccharide antigen ...
    Immune evasion requires a surface polysaccharide produced by all enterococci, known as the enterococcal poly-saccharide antigen (EPA). EPA consists of a cell ...
  47. [47]
    Let Me Upgrade You: Impact of Mobile Genetic Elements on ...
    Aug 9, 2021 · In this review, we discuss enterococcal mobile genetic elements by highlighting their contributions to bacterial fitness, examine the impact of CRISPR-Cas on ...
  48. [48]
    Enterococcal Urinary Tract Infections: A Review of the Pathogenicity ...
    Apr 19, 2023 · This review aims to highlight the pathogenicity, epidemiology, and treatment recommendations (according to the most recent guidelines) of enterococci.
  49. [49]
    Overtreatment of Enterococcal Bacteriuria - JAMA Network
    Jan 9, 2012 · Catheterization was associated with a nearly 2-fold increase in UTI compared with ABU. Having at least 105 CFU/mL of Enterococcus was associated ...
  50. [50]
    Enterococci in Diabetic Foot Infections: Prevalence, Clinical ... - NIH
    May 3, 2023 · Enterococci are common in DFIs and associated with higher rates of amputation and longer hospitalization.Missing: abscesses | Show results with:abscesses
  51. [51]
    Enterococcus faecalis Modulates Immune Activation and Slows ...
    Enterococcus faecalis is one of the most frequently isolated bacterial species in wounds yet little is known about its pathogenic mechanisms in this setting.
  52. [52]
    Surgical Site Infections in Diabetic Patients: Literature Review
    Diabetic patients are more likely to develop SSI as a result of variables such as hyperglycemia, neuropathy, obesity, and peripheral vascular disease.
  53. [53]
    Epidemiological and clinical aspects of urinary tract infection in ...
    A significant bacteriuria has been found in approximately 20% of community-dwelling elderly women and in 10% of older men; this rate almost doubles after 80 ...
  54. [54]
    [PDF] Vancomycin Resistant Enterococci (VRE) - WRHA Professionals
    The incubation period is variable and indefinite. Occurs commonly around 4 - 10 days after exposure.<|separator|>
  55. [55]
    State-of-the-Art Review: Persistent Enterococcal Bacteremia
    Nov 29, 2023 · Enterococcal bacteremia is associated with an imposing 20%–35% 30-day mortality rate, likely at least in some part due to the advanced age, multiple comorbid ...Missing: symptoms | Show results with:symptoms
  56. [56]
    Incidence, clinical characteristics and 30-day mortality of ...
    Apr 1, 2013 · Thirty-day mortality was 21.4% in patients with E. faecalis and 34.6% in patients with E. faecium. Predictors of 30-day mortality included age, ...
  57. [57]
    [PDF] infective-endocarditis-in-adults-diagnosis-antimicrobial-therapy-and ...
    Oct 16, 2018 · In cases with a high suspicion of IE based on either the clinical picture or the patient's risk fac- tor profile such as injection drug use, ...
  58. [58]
    Diagnosis and Management of Infective Endocarditis in People Who ...
    The incidence of injection drug use–associated infective endocarditis has been increasing rapidly over the last decade. Patients with drug use–associated ...
  59. [59]
    Enterococcal Central Nervous System Infections in Children - PubMed
    Mar 26, 2024 · Enterococcal meningitis is rare, especially in healthy neonates. It typically occurs following neurosurgical interventions and may only present with fever and ...
  60. [60]
    Clinical Characteristics of Enterococcus-Associated Peritonitis ... - NIH
    May 30, 2023 · The overall rate of enterococcal infection was 3.2% in PD-associated peritonitis. Edey et al reported that the ratio of diabetes in PD patients ...
  61. [61]
    Enterococcal Infections - Medscape Reference
    Jul 15, 2024 · Enterococcus faecalis and E faecium can cause a variety of infections including cystitis, pyelonephritis and catheter-associated UTI, endocarditis, and mixed- ...
  62. [62]
    Intrinsic and acquired resistance mechanisms in enterococcus - NIH
    This paper reviews the antibiotic resistance mechanisms in Enterococcus faecium and Enterococcus faecalis and discusses treatment options.
  63. [63]
    Macrolide Resistance Genes in Enterococcus spp - PMC - NIH
    Three different mechanisms account for the acquired resistance to MLS antibiotics in gram-positive bacteria: modification of the drug target, inactivation of ...
  64. [64]
    Regulatory circuits controlling enterococcal conjugation - NIH
    Feb 24, 2011 · The regulatory system controlling pheromone-induced plasmid transfer in Enterococcus faecalis is the most thoroughly studied genetic system of this species.
  65. [65]
    Ampicillin-susceptible Enterococcus faecium infections - ASM Journals
    Sep 25, 2023 · Enterococcus faecium is an important human pathogen in which the prevalence of ampicillin resistance is high. However, little is known about the ...
  66. [66]
    Prevalence of aac(6′)-Ie-aph(2″)-Ia resistance gene and its ... - NIH
    The results of this study indicated that aac(6′)-Ie-aph(2′′)-Ia resistance gene is highly prevalent in gentamicin resistant isolates.
  67. [67]
    Antimicrobial Susceptibility Testing for Enterococci - ASM Journals
    Jun 13, 2022 · Use of the E test to predict high-level resistance to aminoglycosides among enterococci. J Clin Microbiol 30:3030–3032. Go to Citation. View.
  68. [68]
    Emergence of Vancomycin-Resistant Enterococci - CDC
    Vancomycin-resistant enterococci (VRE) were first reported in 1986, nearly 30 years after vancomycin was clinically introduced. ... The VanA and VanB operons ...
  69. [69]
    Vancomycin Resistance in Enterococci Due to Synthesis of ...
    Jan 1, 2005 · The second mechanism, which confers a low level of resistance to vancomycin only, involves replacement of d-Ala-d-Ala by a different dipeptide, ...
  70. [70]
    Vancomycin-Resistant Enterococci - PMC - PubMed Central
    The details of vancomycin resistance have been best documented with the vanA gene cluster found on the transposon, or “jumping” genetic element, Tn1546 (7, 11).
  71. [71]
    Emergence and spread of vancomycin resistance among ... - PubMed
    Nov 20, 2008 · Nowadays, six types of acquired vancomycin resistance in enterococci are known; however, only VanA and to a lesser extent VanB are widely prevalent.
  72. [72]
    Vancomycin-Resistant Enterococci: Screening Efficacy and the Risk ...
    Mar 16, 2025 · The latest National Antimicrobial Resistance Surveillance System (AR-ISS) report indicated a percentage of VRE faecium equal to 32.5% in 2023 [6] ...
  73. [73]
    Recommendations for Preventing the Spread of Vancomycin ... - CDC
    Since 1989, a rapid increase in the incidence of infection and colonization with vancomycin-resistant enterococci (VRE) has been reported by U.S. hospitals.
  74. [74]
    Genomic sequencing surveillance of patients colonized with ... - NIH
    Aug 13, 2025 · Our findings describe the high burden of VRE transmission at our hospital and shed light on the importance of using WGS surveillance of both ...
  75. [75]
    Enterococcal Infections Treatment & Management
    Jul 15, 2024 · Infections that do not require bactericidal therapy usually are treated with a single antibiotic directed toward enterococci; these infections ...
  76. [76]
    Infective Endocarditis in Adults: Diagnosis, Antimicrobial Therapy ...
    The 2-week regimen of penicillin or ceftriaxone combined with single daily-dose gentamicin is reasonable for uncomplicated cases of IE caused by highly ...
  77. [77]
    Enterococcus | Johns Hopkins ABX Guide
    Nov 9, 2022 · Risk factors: prolonged hospitalization, hemodialysis, ICU stays with GI and GU manipulation, neutropenia, solid organ transplant (liver), broad ...
  78. [78]
    Vancomycin-resistant enterococcal infections in liver transplant ...
    Aug 5, 2025 · Tedizolid is similar to linezolid, but it is not approved for VRE infections and has limited clinical data for treatment. It has similar ...
  79. [79]
    Clinical Safety: Hand Hygiene for Healthcare Workers - CDC
    Feb 27, 2024 · Hand hygiene with soap and water is superior to alcohol rub and antiseptic wipes for removal of Clostridium difficile. Infect Control Hosp ...Missing: co- | Show results with:co-
  80. [80]
    Hand hygiene with soap and water is superior to alcohol ... - PubMed
    Handwashing with soap and water showed the greatest efficacy in removing C. difficile and should be performed preferentially over the use of alcohol-based ...
  81. [81]
    Supplemental Infection Control Guidelines for the Care of Patients ...
    It is recommended that an antimicrobial agent be used in areas where VRE patients receive care (soap is not as effective in removing transient carriage). The ...
  82. [82]
    Environmental Cleaning Procedures | HAIs - CDC
    Mar 19, 2024 · Typically, chlorine-based disinfectants at 500-5000ppm free chlorine (1:100 or 1:10 dilution of 5% chlorine-bleach; depending on the size of the ...Cleaning Programs · Cleaning Supplies and... · Appendix B1 · Risk-assessment for
  83. [83]
    Controlling Hospital-Acquired Infection: Focus on the Role of ... - NIH
    Bleach-based terminal cleaning was used for an earlier study to control VRE in a hemato-oncology unit, again as part of an intervention package (57).<|separator|>
  84. [84]
    Diagnosis, Prevention, and Treatment of Catheter-Associated ...
    Indwelling catheters should be removed as soon as they are no longer required to reduce the risk of CA-bacteriuria (A-I) and CA-UTI (A-II). 11. Institutions ...Background · Closed Catheter System · Urine Culture And Catheter...<|separator|>
  85. [85]
    [PDF] Guide to the Elimination of Catheter-Associated Urinary Tract ...
    The purpose of this document is to provide evidence-based practice guidance for the prevention of Catheter-Associated. Urinary Tract Infection (CAUTI) in acute ...
  86. [86]
    [PDF] Vancomycin-Resistant Enterococci: Epidemiology, Infection ...
    Dec 1, 2021 · ISSUES AND STRATEGIES IN PREVENTION AND CONTROL OF VANCOMYCIN ... crobials, including daptomycin, supports the use of antimicrobial stewardship to.
  87. [87]
    Improving the Assessment of Vancomycin-Resistant Enterococci by ...
    Overall, routine surveillance prevented the misclassification of 43.0% (unit range, 0%–85.7%) of “incident” carriers on the basis of clinical cultures alone and ...Missing: genomic | Show results with:genomic<|control11|><|separator|>
  88. [88]
    Integrating Genomic Data into Public Health Surveillance for ... - CDC
    Apr 24, 2025 · Integration of genomic and epidemiologic data improved ability to identify additional cases, sensitively classify cases as outbreak or ...
  89. [89]
    The Role of Whole Genome Sequencing in the Surveillance of ...
    Jun 9, 2021 · A scoping review was designed to determine how the use of whole genome sequencing in the surveillance of Enterococcus spp. adds to our knowledge ...
  90. [90]
    Cometabolism of Citrate and Glucose by Enterococcus faecium ...
    It has been assumed that citrate metabolism and lipolysis by enterococci are responsible for the aroma and flavor development in Mediterranean cheeses (5, 14, ...
  91. [91]
    Current Trends of Enterococci in Dairy Products - MDPI
    Another activity of enterococci with an impact upon cheese flavor is their citrate metabolism, which releases several C-4, volatile compounds (e.g., diacetyl, ...
  92. [92]
    Dry-fermented sausages inoculated with Enterococcus faecium ...
    This study evaluated the effects of E. faecium CECT 410 inoculation, either as free cells (CFC) or in alginate beads (CALG), on the ripening and storage of dry ...
  93. [93]
    Novel Starter Strain Enterococcus faecium DMEA09 from Traditional ...
    Enterococci contribute to the sensory development and ripening of fermented foods such as cheese, sausages, and doenjang [11,12,13]. Therefore, they have been ...
  94. [94]
    Randomized, Placebo-Controlled, Double-Blind and Open-Label ...
    Jun 18, 2020 · SF68 is effective and safe in the treatment of acute diarrhea and prevention of antibiotic-associated diarrhea.
  95. [95]
    Probiotics for the Prevention and Treatment of Antibiotic-Associated ...
    May 9, 2012 · The objective of this systematic review and meta-analysis is to evaluate broadly the available evidence on probiotics and synbiotic ...
  96. [96]
    Probiotics in antibiotic-associated diarrhoea - ScienceDirect.com
    Among these, a positive effect of Lactobacillus rhamnosus GG, Bifidobacterium longum and Enterococcus faecium SF68 has been reported. Effectiveness of ...
  97. [97]
    Safety assessment of enterocin-producing Enterococcus strains ...
    Oct 7, 2024 · However, Enterococcus species do not possess GRAS status by the US Food and Drug Administration (FDA) and are not involved in the Qualified ...
  98. [98]
    Evaluation of Enterococcal Probiotic Usage and Review of Potential ...
    Aug 17, 2023 · As indicated previously, the US FDA does not grant Enterococcus GRAS status [6]. Furthermore, Enterococcus is not included in the Qualified ...
  99. [99]
    Exopolysaccharides produced by Enterococcus genus — An overview
    Bioactive potentials of Enterococcus EPS include antioxidant, antibacterial, antibiofilm, anticancer, immunological, prebiotic, and antidiabetic potentials ...
  100. [100]
    A sampling survey of enterococci within pasteurized, fermented ...
    Jul 15, 2021 · Some of these flora can have virulent or antibiotic resistance properties, posing risk to consumers. Others, such as Enterococcus faecalis and ...
  101. [101]
    [PDF] Recreational Water Quality Criteria
    The 1986 recommendations replaced EPA's previously recommended fecal coliform criteria of 200 fecal coliform cfu per 100 mL (U.S. EPA, 1976).
  102. [102]
    [PDF] Method 1600: Enterococci in Water by Membrane Filtration Using ...
    Dec 1, 2009 · Following filtration, the membrane containing the bacterial cells is placed on a selective medium, mEI agar, and incubated for 24 hours at 41°C ...
  103. [103]
    Membrane filtration method - ISO 7899-2:2000
    Detection and enumeration of intestinal enterococciPart 2: Membrane filtration method. Published (Edition 2, 2000).Missing: m- agar
  104. [104]
    Development and Validation of Same-day Monitoring Methods for ...
    Jun 24, 2025 · The qPCR method has been tested in numerous EPA epidemiological studies at freshwater and marine beaches to determine whether a consistent ...
  105. [105]
    Microbial Indicators of Fecal Pollution: Recent Progress and ...
    Arguably, one of the most significant limitations is the inconsistent relationships between FIB occurrence, enteric pathogens, and health risks [25, 27]. In ...Microbial Indicators Of... · Microbial Source Tracking · Molecular Methods...